Alector (Alector) GF Value Rank : 6 (As of Apr. 27, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Alector GF Value Rank?

Alector has the GF Value Rank of 6.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Alector's GF Value Rank

For the Biotechnology subindustry, Alector's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alector's GF Value Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alector's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Alector's GF Value Rank falls into.

Alector GF Value Rank Related Terms

Thank you for viewing the detailed overview of Alector's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Alector (Alector) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alector Inc (NAS:ALEC) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

0Z2:Germany

Address

131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080

Website

https://www.alector.com

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Executives

Sara Kenkare-mitra	officer: President and Head of R&D	C/O ALECTOR, INC, 131 OYSTER POINT BLVD, SUITE 600, SOUTH SAN FRANCISCO CA 94080
Gary Romano	officer: Chief Medical Officer	TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Arnon Rosenthal	director, officer: Chief Executive Officer	C/O ALECTOR, INC., 151 OYSTER POINT BLVD., #300, SOUTH SAN FRANCISCO CA 94080
Marc Grasso	officer: Chief Financial Officer	C/O KURA ONCOLOGY, INC., 3033 SCIENCE PARK ROAD, SUITE 220, SAN DIEGO CA 92121
Terrance Mcguire	director, 10 percent owner	C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
Polaris Venture Management Co. Vi, L.l.c.	10 percent owner	ONE MARINA PARK DRIVE, 8TH FLOOR, BOSTON MA 02210
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Paula Hammond	director	C/O ALECTOR, INC., 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA 94080
Kristine Yaffe	director	C/O ALECTOR, INC., 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO CA 94080
Tillman U. Gerngross	director	C/O ARSANIS, INC., 890 WINTER STREET, SUITE 230, WALTHAM MA 02451
Lavigne Louis J Jr	director	C/O ALLERGAN, INC., 2525 DUPONT DRIVE, IRVINE CA 92612
Elizabeth A. Garofalo	director	C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
David M. Wehner	director	C/O FACEBOOK, INC., 1601 WILLOW ROAD, MENLO PARK CA 94025
Robert King	officer: Chief Development Officer	950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404
Shehnaaz Suliman	officer: President and COO	901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080